Functionalized curcumin analogs as potent modulators of the Wnt/β-catenin signaling pathway

European Journal of Medicinal Chemistry

Volumn 71, Issue , 2014, Pages 67-80

  Leow, Pay Chin ^a   Bahety, Priti ^a   Boon, Choon Pei ^a   Lee, Chong Yew ^a   Tan, Kheng Lin ^a   Yang, Tianming ^a   Ee, Pui Lai Rachel ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Curcumin analog; Drug discovery; Invasion; Osteosarcoma; Wnt signaling

Indexed keywords

1,5 BIS( 4 HYDROXYPHENYL)PENTA 1,4 DIEN 3 ONE; 2,5 BIS( 4 HYDROXYBENZYLIDENE)CYCLOPENTANONE; 2,6 BIS( 3 HYDROXY 4 METHOXYBENZYLIDENE)CYCLOHEXANONE; ALKANE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATIC COMPOUND; BETA CATENIN; CARBON; CURCUMIN; CURCUMIN DERIVATIVE; CYCLOHEXANONE DERIVATIVE; CYCLOPENTANONE DERIVATIVE; GELATINASE B; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; 1,5 BIS (3 METHOXYPHENYL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS (3,4 DIFLUOROPHENYL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS (4 HYDROXYPHENYL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(3 HYDROXY 4 METHOXYPHENYL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(3,4 DIMETHOXYPHENYL)PENTA 1,4 DIEN 3 ONE; 1,5 BIS(4 HYDROXY 3 METHOXYPHENYL)PENTA 1,4 DIEN 3 ONE; 1,5 DIPHENYL PENTA 1,4 DIEN 3 ONE; 1,7 BIS (3,4 DIFLUORO PHENYL) 5 HYDROXY HEPTA 1,4,6 TRIEN 3 ONE; 2,5 BIS(4 HYDROXY 3 METHOXYBENZYLIDENE)CYCLOPENTANONE; 2,5 DIBENZYLIDENE CYCLOPENTANONE; 2,6 BIS(2 FLUOROBENZYLIDENE)CYCLOHEXANONE; 2,6 BIS(3 FLUOROBENZYLIDENE)CYCLOHEXANONE; 2,6 BIS(3 HYDROXY 4 METHOXYBENZYLIDENE)CYCLOHEXANONE; 2,6 BIS(3 METHOXYBENZYLIDENE)CYCLOHEXANONE; 2,6 BIS(3,4 DIFLUOROBENZYLIDENE)CYCLOHEXANONE; 2,6 BIS(3,4 DIMETHOXYBENZYLIDENE)CYCLOHEXANONE; 2,6 BIS(4 FLUOROBENZYLIDENE)CYCLOHEXANONE; 2,6 BIS(4 HYDROXY 3 METHOXYBENZYLIDENE)CYCLOHEXANONE; 2,6 BIS(4 HYDROXYBENZYLIDENE)CYCLOHEXANONE; 2,6 DIBENZYLIDENE CYCLOHEXANONE; 5 HYDROXY 1,7 BIS (3 HYDROXY 4 METHOXY PHENYL)HEPTA 1,4,6 TRIEN 3 ONE; 5 HYDROXY 1,7 BIS (3 METHOXYPHENYL)HEPTA 1,4,6 TRIEN 3 ONE; 5 HYDROXY 1,7 BIS (3,4 DIMETHOXY PHENYL)HEPTA 1,4,6 TRIEN 3 ONE; 5 HYDROXY 1,7 BIS (4 HYDROXY 3 METHOXY PHENYL)HEPTA 1,4,6 TRIEN 3 ONE; 5 HYDROXY 1,7 BIS (4 HYDROXYPHENYL)HEPTA 1,4,6 TRIEN 3 ONE; 5 HYDROXY 1,7 DIPHENYL HEPTA 1,4,6 TRIEN 3 ONE; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INVASION; CELL STRAIN HEK293; CHEMICAL MODIFICATION; CONTROLLED STUDY; CROSS LINKING; DRUG INHIBITION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOSARCOMA CELL; RING OPENING; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION; TRANSLOCATION LINE; WESTERN BLOTTING; ASSAY; DRUG DESIGN; EMBRYO; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; WNT SIGNALING PATHWAY;

CURCUMIN ANALOG; DRUG DISCOVERY; INVASION; OSTEOSARCOMA; WNT SIGNALING;

ANTINEOPLASTIC AGENTS; BETA CATENIN; BONE NEOPLASMS; CELL LINE, TUMOR; CURCUMIN; HEK293 CELLS; HUMANS; NEOPLASM INVASIVENESS; OSTEOSARCOMA; WNT SIGNALING PATHWAY;

EID: 84888108510     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.10.073     Document Type: Article

References (49)

1. C.A. Arndt, and W.M. Crist Common musculoskeletal tumors of childhood and adolescence N. Engl. J. Med. 341 1999 342 352
2. P.A. Meyers, G. Heller, J.H. Healey, A. Huvos, A. Applewhite, M. Sun, and M. LaQuaglia Osteogenic sarcoma with clinically detectable metastasis at initial presentation J. Clin. Oncol. 11 1993 449 453 (Pubitemid 23071040)
3. H.C. Crawford, B.M. Fingleton, L.A. Rudolph-Owen, K.J. Goss, B. Rubinfeld, P. Polakis, and L.M. Matrisian The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors Oncogene 18 1999 2883 2891 (Pubitemid 29250878)
4. T.C. He, A.B. Sparks, C. Rago, H. Hermeking, L. Zawel, L.T. da Costa, P.J. Morin, B. Vogelstein, and K.W. Kinzler Identification of c-MYC as a target of the APC pathway Science 281 1998 1509 1512 (Pubitemid 28425575)
5. O. Tetsu, and F. McCormick Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells Nature 398 1999 422 426 (Pubitemid 29180374)
6. R.C. Haydon, A. Deyrup, A. Ishikawa, R. Heck, W. Jiang, L. Zhou, T. Feng, D. King, H. Cheng, B. Breyer, T. Peabody, M.A. Simon, A.G. Montag, and T.C. He Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma Int. J. Cancer 102 2002 338 342 (Pubitemid 35265873)
7. K. Iwao, Y. Miyoshi, G. Nawa, H. Yoshikawa, T. Ochi, and Y. Nakamura Frequent beta-catenin abnormalities in bone and soft-tissue tumors Jpn. J. Cancer Res. 90 1999 205 209 (Pubitemid 29112321)
8. K. Chen, S. Fallen, H.O. Abaan, M. Hayran, C. Gonzalez, F. Wodajo, T. MacDonald, J.A. Toretsky, and A. Uren Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival Pediatr. Blood Cancer 51 2008 349 355
9. B.H. Hoang, T. Kubo, J.H. Healey, R. Sowers, B. Mazza, R. Yang, A.G. Huvos, P.A. Meyers, and R. Gorlick Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma Int. J. Cancer 109 2004 106 111 (Pubitemid 38160669)
10. Y. Guo, X. Zi, Z. Koontz, A. Kim, J. Xie, R. Gorlick, R.F. Holcombe, and B.H. Hoang Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells J. Orthop. Res. 25 2007 964 971 (Pubitemid 47046444)
11. Y. Guo, E.M. Rubin, J. Xie, X. Zi, and B.H. Hoang Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model Clin. Orthop. Relat. Res. 466 2008 2039 2045
12. P.C. Leow, Q. Tian, Z.Y. Ong, Z. Yang, and P.L. Ee Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells Invest New Drugs 28 2010 766 782
13. D.J. Newman, and G.M. Cragg Natural products as sources of new drugs over the last 25 years J. Nat. Prod. 70 2007 461 477 (Pubitemid 46595760)
14. Y.J. Surh Cancer chemoprevention with dietary phytochemicals Nat. Rev. Cancer 3 2003 768 780
15. C. Sharma, J. Kaur, S. Shishodia, B.B. Aggarwal, and R. Ralhan Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells Toxicology 228 2006 1 15 (Pubitemid 44548099)
16. S. Singh, and B.B. Aggarwal Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected] J. Biol. Chem. 270 1995 24995 25000
17. A.P. Zambre, V.M. Kulkarni, S. Padhye, S.K. Sandur, and B.B. Aggarwal Novel curcumin analogs targeting TNF-induced NF-kappaB activation and proliferation in human leukemic KBM-5 cells Bioorg. Med. Chem. 14 2006 7196 7204 (Pubitemid 44403107)
18. N. Dhillon, B.B. Aggarwal, R.A. Newman, R.A. Wolff, A.B. Kunnumakkara, J.L. Abbruzzese, C.S. Ng, V. Badmaev, and R. Kurzrock Phase II trial of curcumin in patients with advanced pancreatic cancer Clin. Cancer Res. 14 2008 4491 4499
19. S. Balasubramanian, and R.L. Eckert Curcumin suppresses AP1 transcription factor-dependent differentiation and activates apoptosis in human epidermal keratinocytes J. Biol. Chem. 282 2007 6707 6715 (Pubitemid 47100891)
20. Y.J. Surh, S.S. Han, Y.S. Keum, H.J. Seo, and S.S. Lee Inhibitory effects of curcumin and capsaicin on phorbol ester-induced activation of eukaryotic transcription factors, NF-kappaB and AP-1 Biofactors 12 2000 107 112
21. A.C. Bharti, N. Donato, and B.B. Aggarwal Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells J. Immunol. 171 2003 3863 3871 (Pubitemid 37254592)
22. S. Bhattacharyya, D. Mandal, B. Saha, G.S. Sen, T. Das, and G. Sa Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction J. Biol. Chem. 282 2007 15954 15964 (Pubitemid 47100378)
23. R. Blasius, S. Reuter, E. Henry, M. Dicato, and M. Diederich Curcumin regulates signal transducer and activator of transcription (STAT) expression in K562 cells Biochem. Pharmacol. 72 2006 1547 1554 (Pubitemid 44666746)
24. H.Y. Kim, E.J. Park, E.H. Joe, and I. Jou Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia J. Immunol. 171 2003 6072 6079 (Pubitemid 37467228)
25. C. Natarajan, and J.J. Bright Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes J. Immunol. 168 2002 6506 6513 (Pubitemid 34620077)
26. J. Rajasingh, H.P. Raikwar, G. Muthian, C. Johnson, and J.J. Bright Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia Biochem. Biophys. Res. Commun. 340 2006 359 368 (Pubitemid 43021757)
27. M. Saydmohammed, D. Joseph, and V. Syed Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells J. Cell Biochem. 110 2010 447 456
28. Y. Chen, W. Shu, W. Chen, Q. Wu, H. Liu, and G. Cui Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells Basic Clin. Pharmacol. Toxicol. 101 2007 427 433 (Pubitemid 350135350)
29. Z. Wang, Y. Zhang, S. Banerjee, Y. Li, and F.H. Sarkar Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells Cancer 106 2006 2503 2513 (Pubitemid 43787677)
30. A.S. Jaiswal, B.P. Marlow, N. Gupta, and S. Narayan Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells Oncogene 21 2002 8414 8427 (Pubitemid 36061200)
31. M. Kakarala, D.E. Brenner, H. Korkaya, C. Cheng, K. Tazi, C. Ginestier, S. Liu, G. Dontu, and M.S. Wicha Targeting breast stem cells with the cancer preventive compounds curcumin and piperine Breast Cancer Res. Treat. 122 2010 777 785
32. C.H. Park, E.R. Hahm, S. Park, H.K. Kim, and C.H. Yang The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling FEBS Lett. 579 2005 2965 2971 (Pubitemid 40725275)
33. G. Garcea, D.P. Berry, D.J. Jones, R. Singh, A.R. Dennison, P.B. Farmer, R.A. Sharma, W.P. Steward, and A.J. Gescher Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences Cancer Epidemiol. Biomarkers Prev. 14 2005 120 125 (Pubitemid 40165291)
34. R.A. Sharma, S.A. Euden, S.L. Platton, D.N. Cooke, A. Shafayat, H.R. Hewitt, T.H. Marczylo, B. Morgan, D. Hemingway, S.M. Plummer, M. Pirmohamed, A.J. Gescher, and W.P. Steward Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance Clin. Cancer Res. 10 2004 6847 6854 (Pubitemid 39383033)
35. A.L. Cheng, C.H. Hsu, J.K. Lin, M.M. Hsu, Y.F. Ho, T.S. Shen, J.Y. Ko, J.T. Lin, B.R. Lin, W. Ming-Shiang, H.S. Yu, S.H. Jee, G.S. Chen, T.M. Chen, C.A. Chen, M.K. Lai, Y.S. Pu, M.H. Pan, Y.J. Wang, C.C. Tsai, and C.Y. Hsieh Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions Anticancer Res. 21 2001 2895 2900
36. M.M. Yallapu, M. Jaggi, and S.C. Chauhan Curcumin nanoformulations: a future nanomedicine for cancer Drug Discov. Today 17 2012 71 80
37. A. Vyas, P. Dandawate, S. Padhye, A. Ahmad, and F. Sarkar Perspectives on new synthetic curcumin analogs and their potential anticancer properties Curr. Pharm. Des. 19 2013 2047 2069
38. C. Zhao, Z. Liu, and G. Liang Promising curcumin-based drug design: mono-carbonyl analogues of curcumin (MACs) Curr. Pharm. Des. 19 2013 2114 2135
39. G. Liang, L. Shao, Y. Wang, C. Zhao, Y. Chu, J. Xiao, Y. Zhao, X. Li, and S. Yang Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents Bioorg. Med. Chem. 17 2009 2623 2631
40. H. Ohtsu, Z. Xiao, J. Ishida, M. Nagai, H.K. Wang, H. Itokawa, C.Y. Su, C. Shih, T. Chiang, E. Chang, Y. Lee, M.Y. Tsai, C. Chang, and K.H. Lee Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents J. Med. Chem. 45 2002 5037 5042 (Pubitemid 35278699)
41. J.R. Fuchs, B. Pandit, D. Bhasin, J.P. Etter, N. Regan, D. Abdelhamid, C. Li, J. Lin, and P.-K. Li Structure-activity relationship studies of curcumin analogues Bioorg. Med. Chem. Lett. 19 2009 2065 2069
42. M.J. Ryu, M. Cho, J.Y. Song, Y.S. Yun, I.W. Choi, D.E. Kim, B.S. Park, and S. Oh Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300 Biochem. Biophys. Res. Commun. 377 2008 1304 1308
43. P. Anand, A.B. Kunnumakkara, R.A. Newman, and B.B. Aggarwal Bioavailability of curcumin: problems and promises Mol. Pharmacol. 4 2007 807 818
44. K.L. Kirk Selective fluorination in drug design and development: an overview of biochemical rationales Curr. Top. Med. Chem. 6 2006 1447 1456 (Pubitemid 44144927)
45. X. Li, T. Ohtsuki, T. Koyano, T. Kowithayakorn, and M. Ishibashi New Wnt/beta-catenin signaling inhibitors isolated from Eleutherine palmifolia Chem. Asian J. 4 2009 540 547
46. P. Polakis Wnt signaling and cancer Genes Dev. 14 2000 1837 1851 (Pubitemid 30639518)
47. C.R. Dass, E.T. Ek, K.G. Contreras, and P.F. Choong A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma Clin. Exp. Metastasis 23 2006 367 380 (Pubitemid 46197119)
48. X. Qiu, Z. Liu, W.Y. Shao, X. Liu, D.P. Jing, Y.J. Yu, L.K. An, S.L. Huang, X.Z. Bu, Z.S. Huang, and L.Q. Gu Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors Bioorg. Med. Chem. 16 2008 8035 8041
49. G. Liang, S. Yang, L. Jiang, Y. Zhao, L. Shao, J. Xiao, F. Ye, Y. Li, and X. Li Synthesis and anti-bacterial properties of mono-carbonyl analogues of curcumin Chem. Pharm. Bull (Tokyo) 56 2008 162 167 (Pubitemid 351206638)